We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Hands Merge Healthcare Warning Letter

FDA Hands Merge Healthcare Warning Letter

November 19, 2015

Failure to inform the FDA about a medical device correction or removal has earned Merge Healthcare, a developer of medical image handling and processing, interoperability and clinical systems, a warning letter. Word of the letter came just as IBM closed its deal to buy Merge, which will become part of IBM’s new Watson Health business for $1 billion.

According to a warning letter dated Sept. 30, the company issued two notices — one in January and one in April — related to Merge Hemo, which is used as a tool to collect data into the digital patient record. The warning letter states that, in some instances, computers either froze or took multiple short readings of invasive blood pressure as the devices were being used on patients. As a result of having to reboot the systems, patients’ vital signs were lost.

The FDA ultimately determined the company’s actions with the Merge Hemo constituted a Class 2 recall. The letter chides the company for not alerting the agency about the device correction or removal.

QS Problems

During the June 3 to July 27 visit to the company’s Hartland, Wisc., facility, the FDA inspector also found some quality systems issues. Specifically, the inspector determined the company had failed to review and evaluate complaints related to the failure of a device and its labeling.

It also didn’t establish adequate procedures for reviewing these complaints by a formally designated unit.

In a response dated Aug. 12, the company said it was committed to updating its complaint handling procedure. The agency deemed the response inadequate, saying that it failed to update its complaint handling procedure.

Further, the company’s response didn’t include a commitment to performing a retrospective review of quality data sources to ascertain whether there are other complaints that haven’t been appropriately documented or provide a timeframe for establishing a unit to handle complaints.

Design Validation

Also, the company failed to adequately establish procedures for design validation. Specifically, the company allows for devices that have not completed design validation, including software validation, to be shipped to end users for clinical use on patients in a limited availability basis to collect additional feedback prior to the completion of design validation, according to the letter. One product was shipped for clinical use in cardiac catheterization procedure labs under such a release, the FDA says.

While the company says it is committed to updating the design validation procedure, the FDA has determined that its response is inadequate, as it has not provided an implementation timeframe. Further, it doesn’t discuss whether other in-progress projects may be affected by the elimination of the limited availability release.

The FDA also chides the company for not documenting design review results, including the date, in the design history file. 

According to the letter, records fail to indicate when design reviews were conducted or their result. In its response, the company didn’t give an updated procedure for review or a plan for revisiting competed design projects.  

The company is committed to implementing corrective actions to ensure compliance with the Federal Food, Drug, and Cosmetic Act and all regulatory requirements, Justin Dearborn, chief executive officer of Merge Healthcare, says. He adds that company management will work with the agency to ensure the matter is resolved expeditiously.

Don’t become a victim of an FDA Form 483 or warning letter. Order our management report Effective Internal Audits and Quality Control Units for Devicemakers and learn how a strong internal audit program and quality control unit can ensure your compliance with FDA requirements.

Medical Devices Regulatory Affairs

Upcoming Events

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

  • 08Mar

    Medical Device Cybersecurity: The Regulatory Landscape and How to Defend Your Practices During an Inspection

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Boston Scientific’s Single Use Ureteroscope Gets FDA Clearance

  • Gilead’s Trodelvy Gets Expanded Approval in Breast Cancer

  • AI Software to Improve Echocardiogram Images Gets FDA Clearance

  • Rocket Pharmaceuticals Gets RMAT Designation for Danon Disease Gene Therapy

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing